Differential effect of taxol in rat primary and metastatic prostate tumors: Site-dependent pharmacodynamics

Pharmaceutical Research

Volumn 13, Issue 9, 1996, Pages 1305-1312

  Yen, Wan Ching ^a   Wientjes, M Guillaume ^a,b,c   Au, Jessie L S ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

apoptosis; p glycoprotein; pharmacodynamics; primary and metastatic tumors; rat MAT LyLu prostate tumors; taxol

Indexed keywords

PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; DNA SYNTHESIS; DOSE RESPONSE; DRUG LABELING; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LYMPH NODE METASTASIS; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; DNA, NEOPLASM; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; INGUINAL CANAL; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; P-GLYCOPROTEIN; PACLITAXEL; PANCREATIC NEOPLASMS; RATS; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0029952894     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016053412582     Document Type: Article

References (38)

1. E. K. Rowinsky, N. Onetto, R. M. Canetta, and S. G. Arhuck. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19:646-662 (1992).
2. S. G. Arbuck and B. Blaylock. Taxol: Clinical results and current issues in development. In Suffness, M. (ed), Taxol-Science and Applications, Boca Raton, 1995, pp. 379-415.
3. S. B. Horwitz. Taxol (paclitaxel): Mechanism of action. Annuals Oncol. 5:53-56 (1994).
4. K. L. Crossin and D. H. Carney. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and epidermal growth factor. Cell 27:341-350 (1981).
5. Y. Liu, K. Bhalla, C. Hill, and D. G. Priest. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol. 48:1265-1272 (1994).
6. K. Bhalla, A. M. Ilerado, E. Tourkina, C. Tang, M. E. Mahoney, and Y. Huang. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:563-568 (1993).
7. L. Milas, N. R. Hunter, and B. Kurdoglu. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 35:297-303 (1995).
8. M. E. Stearns and M. Wang. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastasis. Cancer Res. 52:3776-3781 (1992).
9. S. B. Horwitz, D. Cohen, S. Rao, I. Ringel, H. J. Shen and C. P. H. Yang. Taxol: Mechanisms of action and resistance. J. Natl. Cancer Inst. 15:55-61 (1993).
10. S. Roy and S. B. Horwitz. A phosphoglycoprotein associated with taxol-resistance in J774.2 cells. Cancer Res. 45:3856-3863 (1985).
11. K. Bhalla, Y. Huang, C. Tang, S. Self, S. Ray, M. E. Mahoney, V. Ponnathpur, E. Tourkina, A. M. Ibrado, and G. Bullock, Characterization of a human myeloid cell line highly resistant to taxol. Leukemia 8:465-475 (1994).
12. L. A. Speicher, L. R. Barone, A. E. Chapman, G. R. Hudes, N. Laning, C. D. Smith, and K. D. Tew. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J. Natl. Cancer Inst. 86:688-694 (1994).
13. G. H. Mickisch, T. Licht, G. T. Merlino, M. M. Gottesman, and I. Pastan. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res. 51:5417-5424 (1991).
14. B. Jachez, R. Nordmann, and F. Loor. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J. Natl. Cancer Inst. 85:478-483 (1993).
15. M. Lenert, S. Emerson, S. D. William, R. de Giuli, and S. E. Salmon. In vitro evaluation of chemosensitizers for clinical reversal of p-glycoprotein-associated taxol resistance. Monogr. Natl. Cancer Inst. 15:63-67 (1993).
16. J. R. Roberts, D. C. Allison, R. C. Sonehower, E. K. Rowinsky. Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res. 50:710-716 (1990).
17. J. E. Liebmann, S. M. Hahn, J. A. Cook, C. Lipschultz, J. B. Mitchell, and D. C. Kaufman. Glutathione depletion of L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 53:2066-2070 (1993).
18. F. C. Lowe, and J. T. Isaacs. Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the Dunning R-3327 rat prostatic adenocarcinoma system as a model. Cancer Res. 44:744-752 (1984).
19. R. A. Vesico, C. H. Redfern, T. J. Nelson, S. Ugoretz, P. H. Stern, and R. M. Huffman. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. U.S.A. 84:5029-5033 (1987).
20. F. H. Schroeder and S. J. Mackensen. Human prostatic adenoma and carcinoma in cell culture-effects of androgen-free culture medium. Invest. Urol. 12:176-181 (1974).
21. D. D. Mickey. Growth and differentiation factors in prostatic tissue. In M. Motta and M. Serio (eds), Hormonal therapy of prostatic diseases: basic and clinical aspects, Medicom, Bussum, The Netherlands, 1988. pp 13-47.
22. M. G. Wientjes, T. G. Pretlow, R. A. Badalament, J. K. Burgers, and J. L.-S. Au. Histocultures of human prostate tissues for pharmacologic evaluation. J. Urol. 153:1299-1302 (1995).
23. D. R. Kohler, and B. R. Goldspiel. Paclitaxel (taxol). Pharmacotherapy 14:3-34 (1994).
24. J. F. R. Kerr, M. Clay, and B. V. Harmon. Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013-2026 (1994).
25. Y. Gan, M. G. Wientjes, D. E. Schuller, and J. L.-S. Au. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 56:2086-2093 (1996).
26. N. M. Lopes, E. G. Adams, T. W. Pitts, B. K. Bhuyan. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32:235-242 (1993).
27. J. Liebmann, J. A. Cook, C. Lipschultz, D. Teague, J. Fisher, and J. B. Mitchell. The influence of Cremophor EL on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother. Pharmacol. 33:331-339(1994).
28. J. L.-S. Au, N. E. Millenbaugh, J. E. Kalns, C. T. Chen, and M. G. Wientjes. Pharmacodynamics of taxol in human solid tumors. Proc. Am. Assoc. Cancer Res. 35:426 (1994).
29. J. L.-S. Au, M. G. Wientjes, T. J. Rosol, A. Koolemans-Beynen, E. A. Goebel, and D. E. Schuller. Histocultures of patient head and neck tumors for pharmacodynamic studies. Pharm. Res. 10:1493-1499 (1993).
30. T. S. Schmittgen, M. G. Wientjes, R. A. Badalament, and J. L.-S. Au. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 51:3849-3856 (1991).
31. Y. Gan, M. G. Wientjes, R. A. Badalament. and J. L.-S. Au. Pharmacodymamics of doxorubicin in human bladder tumors. Clin. Cancer Res. In press (1996).
32. T. Cresteil, B. Monsarrat, P. Alvinerie, J. M. Treluyer, I. Vieira, and M. Wright. Taxol metabolism by human liver microsomes: identification of cytochrome p450 isozymes involved in its transformation. Cancer Res. 54:386-392 (1994).
33. I. Kjonniksen, B. Knut, and O. Fodstad. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide but not to doxorubicin and cisplatin. Cancer Res. 52:1347-1351 (1992).
34. C. Wilmanns, D. Fan, C. A. O'Brian, C. D. Bucana, and I. J. Fidler. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. In. J. Cancer. 52:98-104 (1992).
35. C. Wilmanns, D. Fan, C. A. O'Brian, R. Radinsky, C. D. Bucana, R. Tsan and I. J. Fidler. Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int. Oncol. 3:413-422 (1993).
36. T. Furukawa, T. Kubota, M. Watanabe, T.-H. Kuo, M. Kitajima, and R. M. Huffman. Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. Int. J. Cancer. 54:397-401 (1993).
37. I. J. Fidler, C. Wilmanns, A. Staroselsky, R. Radinsky, Z. Dong, and D. Fan. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metast. Rev. 13:209-222 (1994).
38. B. A. Teicher, T. S. Herman, S. A. Holden, Y. Wang, M. R. Pfeffer, J. W. Crawford, and E. Frei. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457-1461 (1990).